Aikawa Vania, Porter David, Luskin Marlise R, Bagg Adam, Morrissette Jennifer J D
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Cancer Genet. 2015 Dec;208(12):625-9. doi: 10.1016/j.cancergen.2015.10.003. Epub 2015 Nov 3.
Donor cell leukemia is a rare complication of allogeneic hematopoietic stem cell transplantation (HSCT), which may result from the development of a new malignancy in previously healthy donor cells after transplant into the recipient, or it may derive from the transmission of an occult leukemia from donor to recipient. We report a case of donor derived 20q11.2 deletion in a male patient who received an allogeneic HSCT from his HLA-identical sister for the treatment of his chronic lymphocytic leukemia. Bone marrow cells from the donor were found to contain the 20q deletion that expanded over time, but which was absent in her peripheral blood cells. Although cases of donor cell leukemia after HSCT have been reported, in this case there has been no evidence of an associated hematologic neoplasm in either the donor or recipient. Pre-transplant donor bone marrow evaluations are not practical or warranted, however the finding of new cytogenetic abnormalities after transplant mandates a thorough evaluation of the donor.
供体细胞白血病是异基因造血干细胞移植(HSCT)的一种罕见并发症,它可能源于移植到受体后先前健康的供体细胞中出现新的恶性肿瘤,也可能源于供体隐匿性白血病向受体的传播。我们报告一例男性患者,其接受了来自 HLA 相同姐姐的异基因 HSCT 以治疗慢性淋巴细胞白血病,该患者存在供体来源的 20q11.2 缺失。发现供体的骨髓细胞含有随时间扩展的 20q 缺失,但她的外周血细胞中不存在该缺失。虽然已有 HSCT 后供体细胞白血病的病例报道,但在此病例中,供体或受体均无相关血液肿瘤的证据。移植前对供体骨髓进行评估不切实际或无必要,然而移植后发现新的细胞遗传学异常则要求对供体进行全面评估。